Kanna Health is developing KH-001, a unique proprietary form of a naturally-occurring alkaloid, for the treatment of premature ejaculation (PE).

Premature ejaculation (PE) is a distressing condition in which men ejaculate too quickly before or shortly after vaginal penetration (often within less than a minute). There are currently no treatments approved by the FDA, despite the condition affecting up to 20% of men. These men report lower levels of sexual functioning and satisfaction, decreased self-esteem, and higher levels of personal distress. Partners of these men also suffer, and report sexual dissatisfaction and frustration, as well as problems in the relationship.          

​

KH-001 has shown promising results in proof-of-concept animal studies and is set to enter the clinic in 2023.